多西他赛(希存)联合希罗达治疗转移性乳腺癌的临床观察  

Clinical study of docetaxel and capecitabine(xeloda)combination in the treatment of patients with metastatic breast cancer

作　　者：王向明[1] 叶金辉[1] 练英妮[1] 邵剑锋[1] 

机构地区：[1]广东省肇庆市第一人民医院肿瘤科,526021

出　　处：《中国肿瘤临床与康复》2007年第5期457-459,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨多西他赛联合希罗达治疗转移乳性腺癌的疗效及毒副反应。方法30例患者既往使用蒽环类治疗失败，采用多西他赛联合希罗达治疗，多西他赛75mg／m^2，静脉滴注，第1天；希罗达1000mg／m^2。，分2次口服，第1～14天。21d为1周期，2周期后评价疗效，有效者化疗4个周期以上。结果30例患者中，治疗后2例完全缓解（CR），18例部分缓解（PR），8例疾病稳定（SD），2例疾病进展（PD），有效率（CR＋PR）66．7％，肿瘤控制率（CR＋PR＋SD）93．4％。主要毒副反应为骨髓抑制，其中Ⅲ、Ⅳ级白细胞减少占13．3％。Ⅰ、Ⅱ级毒副反应为手足综合征，发生率为26．4％；恶心、呕吐发生率为60．0％；腹泻发生率为20．0％，患者均可耐受。结论多西他赛联合希罗达治疗转移性乳腺癌疗效好．毒副反应可耐受。Objective To evaluate the efficacy and toxicity of docetaxel and xeloda combination regimen in treatment of patients with metastatic breast cancer. Methods Thirty patients who previously failed to respond to adriamycin-based chemotherapy received docetaxel and xeloda combination regimen, namely, docetaxel 75 mg/m^2 ivgtt, dayl and day8 ;xeloda 1000 mg/m^2, twice daily. The regimen was repeated every 21 clays and the clinical response was recorded after two cycles. The effective patients received at least four cycles. Results In these patients, the overall response rate was 66.7% with 2 CR and 18 PR. SD was 8 ,PD was 2. The tumor control rate（ CR ＋ PR ＋ SD） was 93.4%. The main toxic reactions were myelosuppression, grade-3 and 4 adverse events including leucopenia 4 （ 13.3 % ）. Most common grade-1 and 2 adverse events were hand-foot syndrome in 8 cases （26.7%）, nausea and vomiting in 18 （60.0%）, diarrhea in 6 （ 20.0% ）, and were tolerable. Conclusion Good clinical efficacy were achieved in the therapy of metastatic breast cancer with docetaxel and xeloda combination regimen and toxic reactions are tolerable.

关 键 词：多西他赛 希罗达 乳腺肿瘤/化学疗法 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]